Literature DB >> 16139459

[The Nadis cohort: 6236 HIV-infected patients followed up in French university hospitals].

R Agher1, C Duvivier, C Katlama, Y Gérard, Y Yazdanpanah, E Billaud, T Jovelin, F Raffi, P Enel, I Poizot-Martin, P Puglièse, P Dellamonica, M Barone, L Cuzin, B Marchou.   

Abstract

OBJECTIVE: The Nadis electronic medical patient record allows real time constitution of a database including the clinical, therapeutic, biological, and epidemiological features of HIV-positive patients.
METHODS: Data concerning HIV-infected patients followed-up in 6 French University Hospitals was collected. Data quality was assessed on a regular basis in each center.
RESULTS: The 6 first University hospitals using Nadis agreed to group their data on March 15, 2004, concerning 6236 patients having consulted at least once in the previous year. Among these, 29% were female patients, 80% were under treatment on March 15, 2004, 9% were off treatment, 29% were co-infected by hepatitis B or C virus, 57% had an undetectable viral load, 15% of the treated patients were in a worrying immunovirological situation, 358 were diagnosed HIV-positive in 2003. 35% of these "new patients" were women, the mode of infection was sexual in 80%, 45% were under treatment on March 15, 04. This recent data allowed us to have an accurate assessment of this population's management in 2004.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16139459     DOI: 10.1016/j.medmal.2005.06.004

Source DB:  PubMed          Journal:  Med Mal Infect        ISSN: 0399-077X            Impact factor:   2.152


  1 in total

1.  Baseline CD4 cell count and outcome of pegylated interferon plus ribavirin therapy in HIV/hepatitis C virus-coinfected patients.

Authors:  Laure Valerio; Yazdan Yazdanpanah; Isabelle Poizot-Martin; Eric Rosenthal; Catherine Marimoutou; Jean-Albert Gastaut; Albert Tran; Pierre Dellamonica; Kenneth A Freedberg; Christian Pradier
Journal:  J Acquir Immune Defic Syndr       Date:  2008-01-01       Impact factor: 3.731

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.